NASDAQ · Biotechnology

MBX (MBX) Stock

$60.93 -1.09% NASDAQ: MBX Healthcare

Valuation

MetricValue
Price$60.93
Market Cap$2.90B
P/E Ratio-13.02
P/B Ratio2.82
P/S Ratio0.00
EPS (TTM)$-2.38
52-Week High$69.01
52-Week Low$9.48
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-23.58%
ROA-22.60%
ROCE-26.56%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio25.47

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-25.0M$-35.0M$-68.0M$-98.0M
Net Profit$-26.0M$-33.0M$-62.0M$-87.0M
EPS$-0.82$-1.02$-1.85$-2.38
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets$45.0M$84.0M$269.0M$385.0M
Total Liabilities$88.0M$157.0M$11.0M$16.0M
Cash$24.0M$31.0M$49.0M$75.0M
Borrowings$0$0$0$1.0M

Latest News

Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight PR Newswire · Jul 7, 2026 How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy? Simply Wall St. · Jun 15, 2026 MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX) InvestorsHub · Jun 12, 2026 MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell MT Newswires · Jun 12, 2026 MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism GlobeNewswire · Jun 12, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-23.0M$-32.0M$-55.0M$-80.0M
Investing Cash Flow$-12.0M$-31.0M$-161.0M$-86.0M
Financing Cash Flow$0$1.0M$-4.0M$0
Net Cash Flow$12.0M$6.0M$19.0M$26.0M
Free Cash Flow$-24.0M$-32.0M$-56.0M$-82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-7.67%
Quick Ratio30.79
Interest Coverage—
Return 1Y398.29%
Return 3Y—
Return 5Y—

Ownership

Insiders Held2.70%
Institutions Held120.59%
Institutions Float Held123.94%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 6,652,0132026-03-31
Orbimed Advisors LLC.3,637,8872026-03-31
NEA Management Company, LLC3,614,4862026-03-31
Wellington Management Group, LLP3,191,8242026-03-31
Blackrock Inc.2,941,4062026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATXSAstria Therapeutics, Inc. $12.58 +0.00% -7.40 $718.13M 0.00%
AVBP $30.15 +0.33% -8.82 $1.40B 0.00%
DNA $6.93 +1.76% -1.30 $452.70M 0.00%
ERAS $16.76 -6.26% -23.45 $5.82B 0.00%
IOVA $8.28 +1.35% -12.36 $3.70B 0.00%

About MBX

MBX is led by CEO Peter Kent Hawryluk, employs 43 people, headquartered in US, publicly traded since 2000.

MBX stock trades at $60.93 with a market capitalization of $2.90B. The stock is valued at a price-to-earnings (P/E) ratio of -13.02, price-to-book of 2.82, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $9.48 and $69.01, and currently trades 11.7% below its 52-week high.

On profitability, MBX generates a return on equity (ROE) of -23.58%, return on capital employed of -26.56%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides